A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to
cirrhosis patients with ascites despite having received treatment with conventional diuretics
and pharmacodynamics, pharmacokinetics, efficacy, and safety will be investigated.